Susan Glasser
Biographic Data
| ID | 5770679 |
|---|---|
| NAME | Susan Glasser |
| GIVEN NAMES | Susan |
| FAMILY NAME | Glasser |
| SIGNATURE | GLASSER S |
| AFFILIATIONS | Johnson & Johnson (United States) |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 9 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2005 |
| LATEST PUBLICATION YEAR | 2008 |
| H-INDEX | 1 |
Adverse Event Detection in Drug Development
Premarketing studies of drugs, although large enough to demonstrate efficacy and detect common adverse events, cannot reliably detect an increased incidence of rare adverse events or events with significant latency. For most drugs, only about 500 to 3000 participants are studied, for relatively short durations, before a drug is marketed. Systems for assessment of postmarketing adverse events include spontaneous reports, computerized claims or med…
Kremlin Rising
Kremlin Rising
Adverse Event Detection in Drug Development
Premarketing studies of drugs, although large enough to demonstrate efficacy and detect common adverse events, cannot reliably detect an increased incidence of rare adverse events or events with significant latency. For most drugs, only about 500 to 3000 participants are studied, for relatively short durations, before a drug is marketed. Systems for assessment of postmarketing adverse events include spontaneous reports, computerized claims or med…
Adverse effect (1 works) · Biosimilars and Bioanalytical Methods (1 works) · Computational Drug Discovery Methods (1 works) · Development economics (1 works) · Drug (1 works) · Economic history (1 works) · Economic policy (1 works) · Economic system (1 works) · Economics (1 works) · Intensive care medicine (1 works)